PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
27.27%
Revenue growth under 50% of BIDU's 189.31%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
30.32%
Gross profit growth under 50% of BIDU's 189.31%. Michael Burry would be concerned about a severe competitive disadvantage.
80.61%
EBIT growth below 50% of BIDU's 173.93%. Michael Burry would suspect deeper competitive or cost structure issues.
80.61%
Operating income growth under 50% of BIDU's 173.93%. Michael Burry would be concerned about deeper cost or sales issues.
136.94%
Net income growth at 50-75% of BIDU's 234.94%. Martin Whitman would question fundamental disadvantages in expenses or demand.
80.77%
EPS growth under 50% of BIDU's 253.06%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
76.92%
Diluted EPS growth at 50-75% of BIDU's 151.02%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
30.96%
Slight or no buybacks while BIDU is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
33.20%
Diluted share reduction more than 1.5x BIDU's 145.89%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
141.86%
OCF growth of 141.86% while BIDU is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
310.34%
FCF growth of 310.34% while BIDU is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
895.18%
10Y revenue/share CAGR above 1.5x BIDU's 167.42%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
895.18%
5Y revenue/share CAGR above 1.5x BIDU's 167.42%. David Dodd would look for consistent product or market expansions fueling outperformance.
895.18%
3Y revenue/share CAGR above 1.5x BIDU's 167.42%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
412.93%
Net income/share CAGR above 1.5x BIDU's 225.10% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
412.93%
5Y net income/share CAGR above 1.5x BIDU's 225.10%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
412.93%
3Y net income/share CAGR above 1.5x BIDU's 225.10%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.13%
AR growth of 16.13% while BIDU is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
23.88%
Asset growth of 23.88% while BIDU is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
-6.01%
We have a declining book value while BIDU shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-28.57%
We’re deleveraging while BIDU stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-58.80%
Our R&D shrinks while BIDU invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-100.00%
We cut SG&A while BIDU invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.